GleamWall
中文EN

MGX Metagenomi Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1785279 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.7%
TTM net income YoY-10.2%
TTM EPS YoY-23.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-415.5%
Net margin-384.6%
FCF margin-392.0%
EBITDA margin-392.0%

Returns

ROE-49.0%
ROA-34.7%
ROIC (approx.)-49.5%
Asset turnover0.09x

Leverage & solvency

Liabilities / assets30.0%
Debt / equity0.00x
Current ratio6.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.18M—$1.25M$3.91M$8.66M$8.51M$4.13M$9.61M
R&D expense$17.53M$22.51M$19.30M$21.50M$25.28M$22.51M$25.14M$23.16M
SG&A expense$6.88M$6.00M$6.54M$6.78M$6.21M$6.99M$6.80M$7.07M
Operating income-$22.23M-$28.77M-$24.59M-$24.37M-$22.84M-$20.99M-$27.82M-$20.62M
Pretax income-$21.13M-$27.48M-$23.05M-$22.49M-$20.63M-$19.86M-$24.94M-$24.61M
Income tax$0$0$10,000$34,000-$234,000$44,000$98,000-$1.21M
Net income-$21.13M-$27.48M-$23.06M-$22.53M-$20.39M-$19.91M-$25.04M-$23.40M
EBITDA-$20.97M-$27.51M-$23.31M-$23.07M-$21.52M-$19.65M-$26.46M-$19.16M
EPS (basic)-0.56-0.73-0.61—-0.55-0.54-0.68—
EPS (diluted)-0.56-0.73-0.61—-0.55-0.54-0.68—
Weighted avg. shares (diluted)37.78M37.66M37.58M—37.35M37.16M37.02M—
Balance sheet
Cash & equivalents$36.11M$39.03M$25.31M$41.72M$32.77M$26.85M$29.20M$32.63M
Short-term investments$65.57M$81.64M$114.86M$119.08M$151.34M$178.14M$196.78M$220.92M
Receivables$0$0$0$305,000$960,000$900,000$900,000$1.26M
Current assets$110.86M$124.47M$144.56M$165.54M$189.82M$211.68M$233.19M$257.96M
PP&E, net$8.62M$9.90M$11.16M$12.29M$13.89M$15.11M$16.52M$17.74M
Total assets$157.39M$173.70M$196.95M$221.10M$247.94M$272.28M$297.87M$324.60M
Current liabilities$32.34M$27.63M$22.50M$22.93M$29.58M$33.27M$39.89M$37.31M
Total liabilities$64.20M$61.13M$59.17M$62.51M$69.49M$76.45M$85.21M$89.74M
Shareholders' equity$93.19M$112.57M$137.78M$158.60M$178.45M$195.83M$212.66M$234.86M
Shares outstanding37.81M37.78M37.65M37.62M37.55M37.53M37.38M37.42M
Cash flow statement
Operating cash flow-$19.08M-$19.51M-$21.18M-$23.55M-$21.25M-$21.25M-$22.84M-$26.28M
Capital expenditure-$21,000$125,000$25,000$85,000$74,000$127,000$288,000$334,000
Free cash flow-$19.06M-$19.64M-$21.20M-$23.63M-$21.33M-$21.38M-$23.13M-$26.61M
Investing cash flow$16.16M$33.17M$3.99M$32.37M$27.36M$19.07M$24.73M$28.55M
Financing cash flow$0$67,000-$27,000$74,000-$187,000-$166,000-$77,000$0
Depreciation & amortization$1.25M$1.26M$1.27M$1.30M$1.32M$1.33M$1.36M$1.46M
Stock-based compensation$1.78M$2.27M$2.55M$2.69M$3.01M$3.22M$2.93M$3.41M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.